

**ACI Formulations Limited**

**1st Quarter Report 2023-2024**

ACI Formulations Limited

Statement of financial position  
Unaudited


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2023	As at 30 June 2023
<b>Assets</b>			
Property, plant and equipment	5	2,467,212	2,441,710
Right-of-use assets		43,461	47,395
Investments	6	62,614	62,614
<b>Non-current assets</b>		<b>2,573,287</b>	<b>2,551,719</b>
Inventories	8	1,340,739	1,636,264
Trade receivables	9	1,410,780	1,160,288
Other receivables		96,695	81,213
Inter-company receivables	10	754,694	682,777
Advances, deposits and prepayments	11	80,094	32,800
Current tax assets		355,358	353,705
Cash and cash equivalents		177,937	195,260
<b>Current assets</b>		<b>4,216,297</b>	<b>4,142,307</b>
<b>Total assets</b>		<b>6,789,584</b>	<b>6,694,026</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,442,196	1,442,196
Retained earnings		1,217,958	1,140,704
<b>Total equity</b>		<b>3,132,654</b>	<b>3,055,400</b>
<b>Liabilities</b>			
Employee benefits	12	68,555	64,830
Lease liabilities		28,361	31,284
Deferred tax liabilities		197,518	200,663
<b>Non-current liabilities</b>		<b>294,434</b>	<b>296,777</b>
Bank overdrafts		213,813	140,365
Loans and borrowings		2,449,083	2,612,631
Lease liabilities- current portion		12,328	12,440
Trade payables		138,350	75,010
Other payables	13	524,961	477,882
Unclaimed dividend account	14	5,698	5,703
Inter-company payables	15	18,264	17,818
<b>Current liabilities</b>		<b>3,362,497</b>	<b>3,341,849</b>
<b>Total liabilities</b>		<b>3,656,930</b>	<b>3,638,626</b>
<b>Total equity and liabilities</b>		<b>6,789,584</b>	<b>6,694,026</b>
<b>Net asset value (NAV) per share</b>		<b>66.30</b>	<b>64.66</b>

  
Managing Director

  
Director

Chief Financial Officer


  
Company Secretary

ACI Formulations Limited

Statement of profit or loss and other comprehensive income  
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from	
		July 2023 to September 2023	July 2022 to September 2022
Revenue	16	1,430,003	1,292,891
Cost of sales	17	(1,054,162)	(953,786)
<b>Gross profit</b>		<b>375,841</b>	<b>339,105</b>
Other income		2,935	4,763
Administrative, selling and distribution expenses	18	(213,748)	(202,713)
<b>Operating profit</b>		<b>165,028</b>	<b>141,155</b>
<b>Finance costs, net</b>		<b>(56,840)</b>	<b>(39,176)</b>
<b>Profit before contribution to WPPF</b>		<b>108,188</b>	<b>101,979</b>
Contribution to WPPF		(5,409)	(5,099)
<b>Profit before tax</b>		<b>102,779</b>	<b>96,880</b>
Tax expenses		(25,525)	(22,858)
<b>Profit after tax</b>		<b>77,254</b>	<b>74,022</b>
Other comprehensive income		-	-
<b>Total comprehensive income</b>		<b>77,254</b>	<b>74,022</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)		1.64	1.57

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

**ACI Formulations Limited**  
**Statement of changes in equity**  
**Unaudited**

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2023			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2023</b>	472,500	1,442,196	1,140,704	3,055,400
<b>Total comprehensive income</b>				
Profit for the period	-	-	77,254	77,254
<b>Total comprehensive income</b>	-	-	77,254	77,254
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2023</b>	472,500	1,442,196	1,217,958	3,132,654

<i>In Taka</i>	For the 1st quarter ended 30 September 2022			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2022</b>	472,500	1,619,739	1,024,819	3,117,058
<b>Total comprehensive income</b>				
Profit for the period	-	-	74,022	74,022
<b>Total comprehensive income</b>	-	-	74,022	74,022
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2022</b>	472,500	1,619,739	1,098,841	3,191,080

**ACI Formulations Limited**

**Statement of cash flows  
Unaudited**

**Figures in "000"**

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2023 to September 2023	July 2022 to September 2022
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,165,979	1,109,488
Cash paid to suppliers and employees		(904,877)	(1,918,523)
Cash (used in)/generated from operating activities		<b>261,102</b>	<b>(809,035)</b>
Interest paid		(48,979)	(5,976)
Income tax paid		(30,324)	(65,212)
		<b>(79,303)</b>	<b>(71,188)</b>
<b>Net cash (used in)/generated from operating activities*</b>	19	<b>181,799</b>	<b>(880,223)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(35,496)	(24,905)
Investment		-	(18,000)
<b>Net cash (used in)/generated from investing activities</b>		<b>(35,496)</b>	<b>(42,905)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(70,486)	310,455
Proceeds from loans and borrowings		(163,548)	609,422
Payment for lease liability		(3,035)	(1,639)
Dividends paid		(5)	(6)
<b>Net cash (used in)/generated from financing activities</b>		<b>(237,074)</b>	<b>918,232</b>
Net (decrease)/increase in cash and cash equivalents		<b>(90,771)</b>	<b>(4,896)</b>
Cash and cash equivalents as at 1 July		54,895	109,867
<b>Cash and cash equivalents as at 30 September</b>		<b>(35,876)</b>	<b>104,971</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		177,937	218,857
Bank overdraft		(213,813)	(113,886)
		<b>(35,876)</b>	<b>104,971</b>
<b>Net operating cash flow per share (NOCFPS)</b>		<b>3.85</b>	<b>(18.63)</b>


\* See Note 19 for reconciliation of net operating cash flow.


**ACI Formulations Limited**  
**Consolidated Statement of Financial Position**  
**Unaudited**


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2023	As at 30 June 2023
<b>Assets</b>			
Property, plant and equipment	5(a)	2,467,387	2,441,977
Right-of-use assets		43,461	47,395
Investments	6(a)	40,666	40,666
Intangible assets	7	5,148	5,148
<b>Non-current assets</b>		<b>2,556,662</b>	<b>2,535,186</b>
Inventories	8(a)	1,340,739	1,636,264
Trade receivables	9(a)	1,411,451	1,160,848
Other receivables		96,695	81,213
Inter-company receivable	10(a)	747,934	675,914
Advances, deposits and prepayments	11(a)	80,796	33,556
Current tax assets		354,796	353,282
Cash and cash equivalents		180,734	198,057
<b>Current assets</b>		<b>4,213,145</b>	<b>4,139,134</b>
<b>Total assets</b>		<b>6,769,807</b>	<b>6,674,320</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,442,196	1,442,196
Retained earnings		1,213,774	1,136,137
<b>Equity attributable to the owner of the Company</b>		<b>3,128,470</b>	<b>3,050,833</b>
Non controlling interest		1,873	1840
<b>Total equity</b>		<b>3,130,343</b>	<b>3,052,673</b>
<b>Liabilities</b>			
Employee benefits	12	68,555	64,830
Lease liabilities		28,361	31,284
Deferred tax liabilities		197,518	200,663
<b>Non-current liabilities</b>		<b>294,434</b>	<b>296,777</b>
Bank overdrafts		213,813	140,365
Loans and borrowings		2,449,083	2,612,631
Lease liabilities- current portion		12,328	12,440
Trade payables		138,668	75,326
Other payables	13(a)	525,440	478,405
Unclaimed dividend account	14	5,698	5,703
<b>Current liabilities</b>		<b>3,345,030</b>	<b>3,324,870</b>
<b>Total liabilities</b>		<b>3,639,464</b>	<b>3,621,647</b>
<b>Total equity and liabilities</b>		<b>6,769,807</b>	<b>6,674,320</b>
Net asset value (NAV) per share	20	66.21	64.57

  
 Managing Director

  
 Director

  
 Chief Financial Officer

  
 Company Secretary

ACI Formulations Limited

Consolidated statement of profit or loss and other comprehensive income  
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2023 to September 2023	July 2022 to September 2022
Revenue	16(a)	1,430,435	1,293,428
Cost of sales	17(a)	(1,054,162)	(953,786)
<b>Gross profit</b>		<b>376,273</b>	<b>339,642</b>
Other income		2,935	4,763
Administrative, selling and distribution expenses	18(a)	(213,858)	(203,781)
<b>Operating profit</b>		<b>165,350</b>	<b>140,624</b>
Finance costs, net		(56,570)	(39,333)
<b>Profit before contribution to WPPF</b>		<b>108,780</b>	<b>101,291</b>
Contribution to WPPF		(5,409)	(5,099)
<b>Profit before tax</b>		<b>103,371</b>	<b>96,192</b>
Income tax expenses		(25,701)	(22,912)
<b>Profit after tax</b>		<b>77,670</b>	<b>73,280</b>
<b>Other comprehensive income</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income</b>		<b>77,670</b>	<b>73,280</b>
<b>Total comprehensive income attributable to:</b>			
Owners of the Company		77,637	73,373
Non controlling interest		33	(93)
		<b>77,670</b>	<b>73,280</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)	20	1.64	1.55

  
Managing Director

  
Director

Chief Financial Officer

  
Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity  
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2023					
	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2023</b>	472,500	1,442,196	1,136,137	3,050,833	1840	3,052,673
<b>Total comprehensive income</b>						
Profit for the period	-	-	77,637	77,637	33	77,670
<b>Total comprehensive income</b>	-	-	77,637	77,637	33	77,670
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
Capital contribution by non-controlling interest	-	-	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-	-	-
<b>Balance at 30 September 2023</b>	472,500	1,442,196	1,213,774	3,128,470	1,873	3,130,343
	For the 1st quarter ended 30 September 2022					
<i>In Taka</i>	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2022</b>	472,500	1,619,739	1,020,448	3,112,687	(114)	3,112,573
<b>Total comprehensive income</b>						
Profit for the period	-	-	73,373	73,373	(93)	73,280
<b>Total comprehensive income</b>	-	-	73,373	73,373	(93)	73,280
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
Capital contribution by non-controlling interest	-	-	-	-	2,000	2,000
<b>Total transactions with owners of the company</b>	-	-	-	-	2,000	2,000
<b>Balance at 30 September 2022</b>	472,500	1,619,739	1,093,821	3,186,060	1,793	3,187,853



**ACI Formulations Limited**  
**Consolidated statement of cash flows**  
**Unaudited**

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2023 to September 2023	July 2022 to September 2022
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,166,299	1,109,849
Cash paid to suppliers and employees		(904,884)	(1,919,494)
Cash (used in)/generated from operating activities		<b>261,415</b>	<b>(809,645)</b>
Interest paid		(48,709)	(6,134)
Income tax paid		(30,361)	(65,212)
		<b>(79,070)</b>	<b>(71,346)</b>
<b>Net cash (used in)/generated from operating activities*</b>	<b>19 (a)</b>	<b>182,345</b>	<b>(880,991)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(35,496)	(24,905)
<b>Net cash (used in)/generated from investing activities</b>		<b>(35,496)</b>	<b>(24,905)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(71,033)	311,222
Proceeds from loans and borrowings		(163,548)	609,422
Proceeds from share capital		-	2,000
Payment for lease liability		(3,035)	(1,639)
Dividends paid		(5)	(5)
<b>Net cash (used in)/generated from financing activities</b>		<b>(237,621)</b>	<b>921,000</b>
Net (decrease)/increase in cash and cash equivalents		(90,772)	15,104
Cash and cash equivalents as at 1 July		<b>57,693</b>	<b>111,028</b>
<b>Cash and cash equivalents as at 30 September</b>		<b>(33,079)</b>	<b>126,132</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		180,734	240,018
Bank overdraft		(213,813)	(113,886)
		<b>(33,079)</b>	<b>126,132</b>
<b>Net operating cash flow per share (NOCFPS)</b>	<b>20</b>	<b>3.86</b>	<b>(18.65)</b>

\* See Note 19(a) for reconciliation of consolidated net operating cash flow.

**ACI Formulations Limited**

**Notes to the financial statements  
as at and for the 1st quarter ended on 30 September 2023  
Unaudited**

**1 Company profile:**

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

**2 Subsidiaries of ACI Formulations Limited:**

**Neem Laboratories (Pvt.) Ltd.**

Neem Laboratories (Pvt.) Ltd generate its revenue through royalty fees based on the agreement with ACI Limited effective from 1 July 2019 for a tenure of 5 years; the later currently being engaged in the manufacturing of products under the Neem brand name. Since the Subsidiary showed profitability during the year, its ability to operate as a going concern is not at risk. ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

**ACI AgroChem (Pvt.) Ltd.**

ACI AgroChem was incorporated on 22nd June 2022 as a limited Company. The principal activities of the Company is to manufacture and marketing of various kinds of agricultural input like chemical including other allied and general chemical. The Company is yet to start its operation. ACI Formulations Limited through its voting rights (90% share holdings of ACI AgroChem Limited) controls the operating and financing activities of this entity.

**3 Consolidated Financial statements:**

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

**4 Selected explanatory notes:**

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2023. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

**5 Property, plant & equipment**

	<b>Figures in '000'</b>	
	<b><u>30- Sep -23</u></b>	<b><u>30-June -23</u></b>
	<b><u>Taka</u></b>	<b><u>Taka</u></b>
Opening balance	2,842,467	2,714,520
Addition during the period/year	35,496	116,180
Adjustment/disposal during the period/year	-	11,767
	<u>2,877,963</u>	<u>2,842,467</u>
Accumulated depreciation at the end of period/year	<b><u>(410,751)</u></b>	<b><u>(400,757)</u></b>
<b>Closing balance</b>	<b><u>2,467,212</u></b>	<b><u>2,441,710</u></b>

	<u>30- Sep -23</u>	<u>30-June -23</u>
	<u>l aka</u>	<u>l aka</u>
<b>5(a) Consolidated property, plant &amp; equipment</b>		
Opening balance	2,846,167	2,718,220
Addition during the period/year	35,496	116,180
Adjustment/disposal during the period/year	-	11,767
	<u>2,881,663</u>	<u>2,846,167</u>
Accumulated depreciation at the end of period/year	<u>(414,276)</u>	<u>(404,190)</u>
<b>Closing balance</b>	<u><u>2,467,387</u></u>	<u><u>2,441,977</u></u>
<b>6 Investments</b>		
Investment in subsidiaries	21,948	21,948
Investment in FDR	40,591	40,591
Investment in shares of ACI Motors Limited	75	75
	<u>62,614</u>	<u>62,614</u>
<b>6(a) Consolidated investments</b>		
Investment in FDR	40,591	40,591
Investment in Shares- ACI Motors Limited	75	75
	<u>40,666</u>	<u>40,666</u>
<b>7 Intangible assets</b>		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
<b>8 Inventories</b>		
Raw and packing materials	564,172	824,939
Finished goods	622,406	772,983
Goods in transit	152,206	40,865
Other inventories	26,921	25,475
Allowances for slow moving inventory	<u>(24,966)</u>	<u>(27,998)</u>
	<u>1,340,739</u>	<u>1,636,264</u>
<b>8(a) Consolidated inventories</b>		
Raw and packing materials	564,172	824,939
Finished goods	622,682	773,259
Goods in transit	152,206	40,865
Other inventories	26,921	25,475
Allowances for slow moving inventory	<u>(25,242)</u>	<u>(28,274)</u>
	<u>1,340,739</u>	<u>1,636,264</u>
<b>9 Trade receivables</b>		
Related parties	-	-
Other than related parties	1,655,318	1,395,214
	<u>1,655,318</u>	<u>1,395,214</u>
Allowances for doubtful debts	<u>(244,538)</u>	<u>(234,926)</u>
	<u>1,410,780</u>	<u>1,160,288</u>
Below six months	1,195,961	935,604
Over six months	459,357	459,610
Allowances for doubtful debts	<u>(244,538)</u>	<u>(234,926)</u>
	<u>1,410,780</u>	<u>1,160,288</u>
<b>9(a) Consolidated trade receivables</b>		
Related parties	-	-
Other than related parties	1,655,989	1,395,774
	<u>1,655,989</u>	<u>1,395,774</u>
Allowances for doubtful debts	<u>(244,538)</u>	<u>(234,926)</u>
	<u>1,411,451</u>	<u>1,160,848</u>
Below six months	1,196,161	935,692
Over six months	459,828	460,082
Allowances for doubtful debts	<u>(244,538)</u>	<u>(234,926)</u>
	<u>1,411,451</u>	<u>1,160,848</u>

	<u>30- Sep -23</u>	<u>30-June -23</u>
	<u>Taka</u>	<u>Taka</u>
<b>10 Inter-company receivables</b>		
ACI Limited	705,150	635,291
ACI HealthCare Bangladesh Ltd.	42,293	40,416
Neem Laboratories (Pvt.) Ltd.	7,251	7,070
	<u>754,694</u>	<u>682,777</u>
<b>10(a) Consolidated inter-company receivables</b>		
ACI Limited	705,641	635,498
ACI HealthCare USA Inc.	42,293	40,416
	<u>747,934</u>	<u>675,914</u>
<b>11 Advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staffs	427	376
Suppliers & others	29,104	11,454
VAT current account	24,189	(1,094)
	<u>53,720</u>	<u>10,736</u>
<b>Deposits:</b>		
Security deposits	10,231	10,383
LC Margin	9,793	4,571
Bank guarantee margin	4,784	4,784
	<u>24,808</u>	<u>19,738</u>
<b>Prepayments:</b>		
Prepaid expenses	1,566	2,326
	<u>1,566</u>	<u>2,326</u>
	<u>80,094</u>	<u>32,800</u>
<b>11(a) Consolidated advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staff	532	481
Suppliers & others	29,701	12,105
VAT current account	24,189	(1,094)
	<u>54,422</u>	<u>11,492</u>
<b>Deposits:</b>		
Security deposits	10,231	10,383
LC Margin	9,793	4,571
Bank guarantee margin	4,784	4,784
	<u>24,808</u>	<u>19,738</u>
<b>Prepayments:</b>		
Prepaid expenses	1,566	2,326
	<u>1,566</u>	<u>2,326</u>
	<u>80,796</u>	<u>33,556</u>
<b>12 Employee benefits</b>		
Defined benefit obligation	53,583	50,470
Other employee benefits	14,972	14,360
	<u>68,555</u>	<u>64,830</u>
<b>13 Other payables</b>		
Creditor for expenses	405,516	370,273
Advance from customer	-	4,806
Interest payable	58,073	50,212
Security money payable	30,422	28,852
Withholding tax and VAT payable	9,130	7,328
Workers' profit participation fund	21,820	16,411
	<u>524,961</u>	<u>477,882</u>

	<u>30- Sep -23</u>	<u>30-June -23</u>
	<u>Taka</u>	<u>Taka</u>
<b>13(a) Consolidated other payables</b>		
Creditor for expenses	405,995	370,796
Advance from customer	-	4,806
Interest payable	58,073	50,212
Security money payable	30,422	28,852
Withholding tax and VAT payable	9,130	7,328
Provision for workers' profit participation fund	21,820	16,411
	<u>525,440</u>	<u>478,405</u>
<b>14 Unclaimed dividend account</b>		
Unclaimed/ unpaid dividend	5,698	5,703
	<u>5,698</u>	<u>5,703</u>
<b>15 Inter-company payables</b>		
ACI AgroChem Limited	18,264	17,818
	<u>18,264</u>	<u>17,818</u>
	for the period from	
	July 2023 to	July 2022 to
	September	September
	<b>2023</b>	<b>2022</b>
	<u>Taka</u>	<u>Taka</u>
<b>16 Revenue</b>		
Crop Care & Public Health	1,151,644	1,065,191
Mosquito Coil	1,118	1,692
Aerosol	191,290	109,925
Paint	82,467	111,912
Others	3,484	4,171
	<u>1,430,003</u>	<u>1,292,891</u>
<b>16(a) Consolidated revenue</b>		
Crop Care & Public Health	1,151,644	1,065,191
Mosquito Coil	1,118	1,692
Aerosol	191,290	109,925
Paint	82,467	111,912
Others	3,916	4,708
	<u>1,430,435</u>	<u>1,293,428</u>

		for the period from	
		July 2023 to September 2023 <u>Taka</u>	July 2022 to September 2022 <u>Taka</u>
<b>17</b>	<b>Cost of sales</b>		
	Opening stock	1,597,922	1,220,121
	Purchase	594,224	1,780,110
	Stock write off	(6,635)	(15,680)
		<u>2,185,511</u>	<u>2,984,551</u>
	Closing stock	(1,186,578)	(2,085,425)
		<u>998,933</u>	<u>899,126</u>
	Manufacturing expenses	55,229	54,660
		<u>1,054,162</u>	<u>953,786</u>
<b>17(a)</b>	<b>Consolidated cost of sales</b>		
	Opening stock	1,598,198	1,220,397
	Purchase	594,224	1,780,110
	Stock write off	(6,635)	(15,680)
		<u>2,185,787</u>	<u>2,984,827</u>
	Closing stock	(1,186,854)	(2,085,701)
		<u>998,933</u>	<u>899,126</u>
	Manufacturing expenses	55,229	54,660
		<u>1,054,162</u>	<u>953,786</u>
<b>18</b>	<b>Administrative, selling and distribution expenses</b>		
	Administrative expenses	57,440	47,707
	Distribution expenses	33,379	32,984
	Selling expenses	122,929	122,021
		<u>213,748</u>	<u>202,713</u>
<b>18(a)</b>	<b>Consolidated administrative, selling and distribution</b>		
	Administrative expenses	57,549	48,774
	Distribution expenses	33,379	32,985
	Selling expenses	122,930	122,021
		<u>213,858</u>	<u>203,781</u>
<b>19</b>	<b>Reconciliation of net operating cash flow</b>		
		for the period from	
		July 2023 to September 2023	July 2022 to September 2022
<i>In Taka</i>			
	Profit after tax	77,254	74,022
	Adjustment for non cash items and others:		
	- Depreciation and amortization	9,994	11,197
	- Provisions	4,126	(12,977)
	- Net finance cost	7,861	33,199
	- Unrealized gain/(loss) on translation of foreign currency receiv	(986)	(2,126)
	- Tax expense	(4,799)	(42,353)
	- Contribution to WPPF	5,409	5,099
	Changes in:		
	- Inventories	302,160	(893,328)
	- Trade and other receivables	(275,585)	(188,374)
	- Advances, deposit and prepayments	(47,786)	(17,724)
	- Trade and other payables, employment benefits <sup>1</sup>	104,151	153,142
	Cash generating from operating activities	<u>181,799</u>	<u>(880,223)</u>

19 (a)

**Reconciliation of consolidated net operating cash flow**

<i>In Taka</i>	<b>for the period from</b>	
	<b>July 2023 to September 2023</b>	<b>July 2022 to September 2022</b>
Profit after tax	77,670	73,280
Adjustment for:		
- Depreciation and amortization	10,364	11,289
- Bad debts and inventory loss/(recovery)	4,126	(12,977)
- Net finance cost	7,861	33,199
- Unrealized gain/(loss) on translation of foreign currency receiv	(986)	(2,126)
- Tax expense	(4,661)	(42,300)
- Contribution to WPPF	5,409	5,099
Changes in:		
- Inventories	302,161	(893,328)
- Trade and other receivables	(275,698)	(188,550)
- Advances, deposit and prepayments	(47,733)	(17,724)
- Trade and other payables, employment benefits'	103,832	153,147
Cash generating from operating activities	182,345	(880,991)

20 **Consolidated EPS, NAV per Share and NOCFPS:**

	<b>for the period upto</b>	
	<b>July 2023 to September 2023</b>	<b>July 2022 to September 2022</b>
Weighted average number of ordinary shares (in thousand)	47,250	47,250
Consolidated profit attributable to equity holders of the Company (Taka '000)	77,637	73,373
Earnings per share (Taka)	1.64	1.55
Consolidated cash flows from operating activities (Taka '000)	182,345	(880,991)
Net operating cash flows per share (NOCFPS)	3.86	(18.65)
	<b><u>30- Sep -23</u></b>	<b><u>30-June -23</u></b>
	<b><u>Taka</u></b>	<b><u>Taka</u></b>
Consolidated net asset attributable to equity holders of the Net asset value (NAV) per share	3,128,470	3,050,833
	66.21	64.57

Consolidated revenue increased by around 11% over SPLY mainly due to higher sales in CC&PH, Contract Manufacturing business. Higher sales alongwith changes in product mix in CC&PH business, led to increase overall gross profit by 11% over SPLY whereas overall operating expenses increased by 5% due to efficient and effective control over operating cost. However, despite having higher financing cost mainly due to higher interest rate and utilization of working capital in line with increased sales, higher GP and controlled operating cost led to consolidated profit after tax of Tk. 77.67 Mn against Tk 73.28 Mn of SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS increased due to liquidation of inventory and efficient working capital management .

## 21 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

**Crop Care and Public Health (CC & PH)** To manufacture and sell crop care and public health products.

**Mosquito Coil (M Coil)** To manufacture and sell mosquito coil products

**Aerosol** To manufacture and sell aerosol and air freshener products.

**Paint** To manufacture and sell of paint products.

**Figures in '000'**

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on	
	30-Sep-23	30-Sep-22	30-Sep-23	30-Sep-22	30-Sep-23	30-Sep-22	30-Sep-23	30-Sep-22	30-Sep-23	30-Sep-22	30-Sep-23	30-Sep-22
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	1,151,644	1,065,191	1,118	1,692	191,290	109,925	82,467	111,912	3,266	3,566	1,429,785	1,292,286
Inter-segment revenues	-	-	-	-	-	-	-	-	650	1,142	650	1,142
Total revenue	1,151,644	1,065,191	1,118	1,692	191,290	109,925	82,467	111,912	3,916	4,708	1,430,435	1,293,428
Financing costs	(41,830)	(27,995)	(220)	(3)	(6,809)	(6,015)	(6,855)	(4,842)	(856)	(478)	(56,570)	(39,333)
Depreciation	(4,808)	(4,704)	(2,985)	(3,922)	(1,154)	(1,070)	(921)	(1,326)	(218)	(267)	(10,086)	(11,289)
Cost of sales excluding depreciation	(791,869)	(746,022)	(8,581)	(10,564)	(176,566)	(94,585)	(64,774)	(89,439)	(5,148)	(5,052)	(1,046,938)	(945,662)
Operating expenses excluding depreciation	(170,690)	(156,674)	(2,302)	(2,548)	(2,962)	(2,594)	(34,904)	(38,289)	(138)	(511)	(210,996)	(200,616)
Other income /(expense)	1,226	2,474	-	-	40	17	383	147	1,286	2,125	2,935	4,763
<b>Profit before tax</b>	<b>136,489</b>	<b>125,657</b>	<b>(12,322)</b>	<b>(14,578)</b>	<b>3,647</b>	<b>5,394</b>	<b>(23,374)</b>	<b>(20,745)</b>	<b>(1,100)</b>	<b>465</b>	<b>103,371</b>	<b>96,192</b>
<b>Reportable segment assets</b>	<b>2,848,226</b>	<b>2,962,783</b>	<b>192,860</b>	<b>185,387</b>	<b>655,509</b>	<b>557,010</b>	<b>561,922</b>	<b>545,345</b>	<b>2,511,290</b>	<b>2,423,795</b>	<b>6,769,807</b>	<b>6,674,320</b>
<b>Reportable segment liabilities</b>	<b>670,901</b>	<b>813,444</b>	<b>16,078</b>	<b>13,548</b>	<b>216,196</b>	<b>158,703</b>	<b>171,041</b>	<b>180,455</b>	<b>2,565,248</b>	<b>2,455,497</b>	<b>3,639,464</b>	<b>3,621,647</b>

\* Comparative figures of segment assets and segment liabilities are as of 30 June 2023.

22 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.